肺癌中MET激活和对向治疗的反应
Sarah Anna Okun1,2, Daniel Lu3, Katherine Sew1,2
1Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Cancers
|January 25, 2025
概括
异常的肝细胞生长因子受体 (MET) 信号驱动癌症. 由于耐药性机制,MET氨酸激酶抑制剂 (TKI) 的有效性有限,因此需要进一步研究以克服这些挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞生长因子受体 (MET) 是一种受体氨酸激酶 (RTK),对细胞生长和生存等过程至关重要.
- 异常的MET活性,通常是由于MET放大 (METamp) 或MET外显子14跳转 (METex14) 等突变,驱动瘤发生,特别是在肺癌中.
- MET是关键的治疗标,导致了MET氨酸激酶抑制剂 (TKI) 的发展.
研究的目的:
- 审查当前对MET阳性癌症的治疗环境.
- 探索潜在的各种机制,初级和获得的耐药性对MET技术技术.
- 突出需要策略来克服MET驱动癌症的治疗耐药性.
主要方法:
- 对癌症中MET信号研究的文献综述.
- 对MET向治疗的临床数据的分析.
- 检查对MET抑制剂耐药性的分子机制.
主要成果:
- 在包括肺癌在内的各种癌症中,MET变化很常见.
- 由于显著的耐药性,MET TKIs已经显示出有限的临床疗效.
- 抵抗机制通常涉及非目标或绕过信号通路,从而逃避MET抑制.
结论:
- 尽管有针对性的疗法,但耐药性仍然是治疗MET阳性癌症的主要挑战.
- 了解耐药机制对于开发更有效的治疗策略至关重要.
- 需要进一步的研究,以改善MET驱动恶性瘤患者的临床结果.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.7K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Tumor Immunotherapy
466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
